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Abstract
Objective: The infectious corona virus, COVID-19 has 
high case mortality in those whom suffer with severe symp-
toms requiring hospitalisation. A major problem associated 
with COVID-19 is the spread of infection by a-symptomatic 
carriers, or those with mild symptoms. We aim to determine 
the antibody prevalence in a professional Welsh cohort and 
begin to explore the longevity of COVID-19 antibodies. 
Methods: 739 Cardiff Metropolitan University staff mem-
bers took part in an observational study to determine the 
prevalence of COVID-19 antibodies in a two-phase, single 
cohort study. All participants were tested for IgM and IgG 
antibodies against COVID-19 using a lateral flow detection 
assay. Venous blood samples from positive participants and 
a randomly selected negative population were collected to 
confirm antibody titre, using two gold standard immunoas-
says, carried out independently by the Specialist Virology 
Centre, UHW. 
Results: 3.65% of the population tested positive for anti-
bodies against COVID-19, with a higher prevalence seen in 
male participants (5% vs. 2.73% of females). In addition to 
gender, both pre-existing asthma and age were key deter-
minants in antibody positivity. 78.26% retained antibodies 
at the 3 months follow up test. 36.36% of females lost anti-
body positivity between the 3 - and 6 - month time points 
compared with 8.3% of males. Lateral flow antibody testing 
was shown to have 96% sensitivity and 95% specificity com-
pared with standard tests.
Conclusion: We conclude that prevalence of COVID-19 
antibodies is evident in the asymptomatic population, and 
in 78.26% of those initially antibody positive prevails at ap-
proximately 6 months from perceived time of exposure. 
Males are 4 times more likely to retain antibodies for longer 
than females.
Keywords: COVID-19. Epidemiology; Gender; COVID-19 anti-
bodies.
MedDocs Publishers
2Annals of Epidemiology and Public health
Introduction
COVID-19 is an infectious corona virus, with a high case fatal-
ity rate caused by severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2), first identified in Wuhan in China, in Decem-
ber 2019[1]. The ongoing mass spread of COVID-19 has been 
attributed to transmission of respiratory droplets, aerosols and 
contaminated surfaces [2]. Despite COVID-19 being declared by 
the World Health Organisation as a public health emergency of 
international concern, at the end of January 2020, the majority 
of COVID-19 cases were a-symptomatic or associated with mild 
symptoms [3]. Some patients have and continue to progress to 
have severe pneumonia-like symptoms that can require hos-
pitalisation. During the first phase of the COVID-19 pandemic 
and at the time of initiating this study, the majority of research 
investigating COVID-19 outcomes and antibody prevalence had 
focused primarily on patients with severe disease, often those 
receiving intensive care where mortality rate was as high as 
59% (between January and March)[13]. More recently, data has 
emerged from a number of studies in a-symptomatic cohorts 
including UK Biobank [4], Imperial [5] and Iceland [6]. Our study 
focuses on COVID-19 antibody prevalence in a single cohort of 
largely a-symptomatic participants at two time points, compar-
ing Lateral Flow Testing (LFT) to two clinically applied standard 
immuno-methods.
After infection with COVID-19, most (but not all) people will 
develop antibodies against the virus [7,8]. The extent of anti-
body response and lifetime depends on several factors includ-
ing the extent of exposure, individual immune system respon-
siveness and pre-existing conditions [9]. Several high through 
put lateral flow immunoassays were developed by a number of 
companies early during the pandemic in response to the crisis 
and the limited availability of gold standard Polymerase Chain 
Reaction (PCR) detection of virus. These were recognised to 
have several advantages including detection of both IgM and 
IgG antibodies within ten minutes, the wide scale availability, 
low cost, and their ease of use [14]. These stimulated early lim-
ited scale population sera-surveillance to be carried out, such 
as, in Southampton (545, a-symptomatic healthcare workers) 
[10] and in the Isle of Wight (1 third of healthcare workers) [15]. 
The potential for these assays to inform incidence of COVID-19 
infection and antibody prevalence locally and nationally was at-
tractive. However, results from these studies found LFT to have 
lower sensitivity and specificity in practice in comparison to PCR 
for virus and clearly did not report on current status of viral in-
fection. They were therefore deemed largely inappropriate for 
wide scale adoption across the asymptomatic population at 
that time, with high sensitivity PCR capacity being focussed on 
those individuals who were symptomatic.
Determining antibody prevalence within the community 
could play an important role in increasing our understanding of 
the pathophysiology and epidemiology of COVID-19, not only 
will this allow those people who have developed an immune 
response to COVID-19 to be identified but serial testing will 
provide valuable insight into the longevity of antibodies in re-
sponse to COVID-19 infection. Ultimately, antibody prevalence 
in conjunction with the T cell adaptive immune response may 
convey a level of immunity that would help prevent re-infection 
or reduce COVID-19 disease severity – the basis of vaccination. 
Recognising the wide scale applicability of LFT and by employ-
ing the product with the highest sensitivity and specificity com-
mercially available at the time, we investigated the usefulness 
of high through - put LFT for antibody measurement and deter-
mined the test’s sensitivity and specificity by comparing its re-
sults to two gold standard, high sensitivity immune assays car-
ried out independently by the Specialist Virology Centre, UHW.
We aimed to determine antibody prevalence in a low risk, 
a-symptomatic cohort who had been in UK “lockdown” since 
mid-March, and track these over the ensuing period of uncer-
tainty as we approached and entered a second phase of acute 
widespread infection. We believe that results from our cohort 
may be representative of the larger population of professionals, 
asked to work from home in accordance with Welsh govern-
ment guidelines March through November. 
Methods 
All full time Cardiff Metropolitan University staff were invited 
in July 2020 to participate in an antibody screening programme, 
739 participants were tested during this study. 
The cohort 
Staff who worked from home, with immediate effect from 
17th March 2020. Essential staff only returning to campus on a 
part time basis, where appropriate COVID-19 risk could be miti-
gated. 
Screening for SARS-CoV-2 IgM and IgG antibodies
Volunteers were invited to participate in phase 1 of screen- 
ing via the University staff portal and newsletter and booked an 
individual appointments at the facility using an online book- ing 
system (Outlook)  where they were assigned a unique identi-
fying code. A detailed participant information sheet was also 
provided through this medium.
All participants were asked to fill in a brief background and 
medical questionnaire prior to each test. This questionnaire 
included questions relating directly to COVID-19 exposure and 
perceived risk at both time points, as well as gathering general 
health information.
During the allotted 30min appointment, rapid testing was 
carried out using the FDA approved Confirm BioSciences ® 
(California) test against SARS-CoV-2, for both IgM and IgG anti-
bodies using the manufacturer’s guidelines. Briefly, finger prick 
blood (capillary) samples were collected from all participants 
and approximately 10µL of capillary blood was transferred into 
the test window. Buffer (provided with test) was added to the 
sample and the test was left to develop. Following 10 minutes 
the test window was read and interpreted as suggested by the 
manufacturer guidelines. Confirm Biosciences® report a speci-
ficity of 98% and sensitivity of 100% for this test when used in 
clinical samples (Specificity and sensitivity have been disputed 
by FDA; however, the test remains commercially available).
All those who tested positive for IgM and/or IgG antibodies 
and a matched number of individuals who tested negative were 
randomly selected to give a venous blood sample. Serum was 
isolated from these samples and sent to the Specialist Virology 
Centre, UHW to determine antibody titres using gold standard 
Abbott® and Euroimmun® antibody tests. These tests were un-
dertaken entirely independently and blind to the screening re-
sult and to subject details. 
Three months following the original antibody test, subjects 
who tested positive and those selected previously as negative 
controls were invited to be re-tested in phase 2 of screening. 
This test was a repeat of the original rapid antibody test using 
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capillary blood and the collection of a venous blood sample for 
analyses.
Ethics 
This study was approved by the Cardiff Metropolitan Uni-
versity Ethics Committee (ref# sta-2860) and was conducted in 
line with the principles outlined in the Declaration of Helsinki. 
Standard operating procedures were approved and monitored 
throughout by University Health and Safety and the COVID-19 
Response Group as part of the study risk assessment.
Statistical analysis 
Test sensitivity and specificity was determined using a stan-
dard binary classification test, which determined matched neg-
ative and positive results across the 3 different antibody tests 
undertaken. Health questionnaire and participant data were 
logged online and later analysed using the University secure 
Qualtrics based system. Where two groups were compared an 
unpaired T-test was used to determine differences between 
groups. Significance is determined as p<0.05. 
Results 
Phase 1 Results 
By LFT antibody test, 3.65% of the 739-population tested 
positive for COVID-19 antibodies (IgM and/or IgG). 
Furthering this, 26 participants had been previously tested 
for COVID-19 virus, via PCR through the Public Health Wales CO-
VID-19 testing units. Of these, 3 participants were tested virus 
positive, however only 1 of these participants showed positive 
for either IgM or IgG COVID-19 antibodies in our study. 
Of those tested, 5% of the male population and 2.73% of 
the female population tested positive for COVID-19 antibod-
ies. The average age of positive participants was 44.5 years vs. 
42.91years for negative participants (cohort ages detailed be-
low in table 1). Of those participants who tested positive for CO-
VID-19 antibodies, 34.6% were aged 40 and under. The highest 
prevalence of COVID-19 antibodies was observed in males aged 
between 61 and 70 (6.67% prevalence). 
The medical questionnaire was completed by all participants 
at both testing appointments. From the population data collect-
ed a disproportionate risk is highlighted in those with pre-ex-
isting health conditions. Participants who reported being asth-
matic made up 33.3% of the positive antibody population, while 
7.4% reported being diagnosed with hypertension. A minority 
of the positive cohort reported a further underlying condition, 
including type 1 diabetes or cardiovascular pathology.
Smoking did not associate with positive COVID-19 antibody 
tests, with 4.55% of the positive population indicating they 
smoke regularly. Smokers made up a comparable 5.5% of the 
antibody negative population. 
Phase 2 Results  
All participants whom tested antibody positive and a 
matched number of antibody negative controls were invited 
back for screening in phase 2 of the study. Of those invited, 
79.69% returned. 
Of those who originally tested negative 96.43% remained 
negative and 3.57% showed new antibody positivity. Of those 
whom originally tested positive 78.26% remained positive, 
however 21.74% showed a negative test result. Of those whom 
sera-converted from antibody positive to antibody negative 
80% were female.
Comparison of antibody test methodologies
Blinded comparison between all positive antibody tests and 
randomly selected negative controls, of LFT and two indepen-
dent antibody testing methods was undertaken. The prevalence 
data collected from LFT showed 92.85% agreement with the Eu-
roimmun® (Figure 1a) and 78.57% agreement with the Abbott 
Diagnostic® test (Figure 1b).
Comparison with both Abbot and Euroimmun® antibody 
tests showed our test to have a specificity of 95% and a sensitiv-
ity of 89%. It is important to note that both these tests detect 
only IgG presence. LFT also detects IgM and given only IgM was 
detected in an additional 7% of participants, this results in an 
overall sensitivity of 96%.
Gender differences in antibody titre
Antibody titres between male and female positive partici-
pants were compared for both the Euroimmun® (Figure 2A) 
and Abbott® (Figure 2B) antibody tests. The Euroimmun® test 
shows no significant difference in positive antibody titres be-
tween male and female participants. However, in the Abbott® 
test males had significantly (p=0.0024) higher antibody titres 
than antibody positive females.
Figure 1: Comparison between LFT results and (A) Euroim-
mun® antibody titre and (B) Abbott Diagnostic® antibody titre.
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Figure 2: Antibody Titres in positive males and females. Com-
parison of antibody titres in (A) Euroimmun® antibody test and (B) 
Abbott ® antibody test. Each compare blood antibody titres in both 
male (N=13) and female (N=10) participants from phase 1 of the 
study. **=p<0.01.
Table 1: Cohort Age Data.




Total Number of 
Males
Total Number Tested 739 439 300
Positive IgM +/- IgG 28 13 15
Average Age 43.45 Years 43.3 Years 43.63 Years
Average Positive Age 44.5 Years 43.21 Years 45.79 Years
Average Negative Age 42.91 Years 42.3 Years 43.52 Years
Discussion
This study brings important data to the ever-progressing field 
of COVID-19 antibody prevalence and is a first of its kind study 
to demonstrate the change in antibody prevalence in a single 
cohort of asymptomatic participants over 6 months in Wales. 
We confirm the usefulness of rapid screening using LFT in com-
parison to standard methodology and apply these to identify 
a potential difference in the longevity of antibodies between 
males and females. 
The reason why male and female antibody prevalence differs 
in this asymptomatic cohort (5% v 2%, respectively) is currently 
unknown, but could be due to an impaired immune response 
in post-menopausal women, linked to the loss of sex hormones 
[11]. The females who sera-converted in this study were on av-
erage 10 years older than those females whom maintained an-
tibody positivity (mean age 54.5Years v. 45.5Years respectively). 
A significant difference is also seen in the antibody titres mea-
sured in male versus female antibody positive participants, with 
females exhibiting significantly lower levels. This may go some 
way in explaining why 80% of those who became antibody 
negative in phase 2 of this study were females. Similar gender 
differences have been observed with the effectiveness of both 
seasonal and pandemic influenza vaccinations and are linked 
with, cytokine, antibody and memory immune responses [12]. 
The fact that gender differences exist in both morbidity and 
mortality associated with COVID-19 has recently been identi-
fied [18]. A recent, large-scale meta-analysis has determined 
that although there is no difference in the proportion of males 
and females being infected with COVID-19, males are three 
times more likely than females to require ICU treatment and 
have higher mortality following infection [18]. This study also 
confirms males to have a higher antibody titre than females 
with a similar viral exposure, with females showing a higher 
T-cell response [18]. Further studies are required to deter-
mine why females having lower antibody titre in response to 
COVID-19 infection do not progress to have disease as severe 
as their male counterparts. Sex differences in both innate and 
adaptive immunity go some way in explaining this potential dis-
parity, where females have a higher number of CD4+ [19] and 
CD8+ [20] T-cells, offering a further level of immune protection. 
Further work should focus on how antibody lifetime dictates 
susceptibility to ongoing effects of COVID-19, for example, long 
COVID, or indeed future infection with COVID-19. 
The measured antibody prevalence of 3.65% is lower than 
the suggested national average (4-6%), as suggested by the UK 
REACT study, that showed antibody prevalence in July across 
the UK was 6%, decreasing to 4.8% in August and 4.4% in Sep-
tember [5]. Prevalence is also lower than that suggested by UK 
Biobank (4.7%) [4] based on a similar sized Welsh cohort, which 
also highlighted greater prevalence in areas of high popula-
tion density (5.8% in Cardiff, 10% London) ranging from 2.8% 
in rural locations. A lower prevalence of COVID-19 antibodies 
was potentially seen in our cohort of professional staff as the 
vast majority were able and advised to work from home during 
the period March through September 2020, with a continua-
tion where possible (applying a blended mix of 30% face-to-face 
teaching and 70% online learning) throughout October-Decem-
ber, suggesting a potential lower viral exposure. 
The results presented in this study agree with numerous 
studies which suggest that age is a key determinant in COVID-19 
infection. However, the results potentially disagree with those 
suggesting that lower infection rates are seen in older partici-
pants [4], since 65.4% of the antibody positive participants in 
our study were aged 41 and above, with highest prevalence oc-
curring in males aged 61-70 years. Thus, it may be suggested 
on the basis of antibody prevalence, of the working population, 
older employees are potentially more at risk of COVID-19 than 
their younger colleagues. 
This study reports an LFT method that has both high sensi-
tivity (96%) and specificity (95%) used to confirm presence of 
COVID-19 antibodies. The practical benefits of using a sensitive 
and specific LFT for antibodies could aid our understanding of 
antibody prevalence in large populations, as well as the poten-
tial in tracking antibody response over time following COVID-19 
vaccination. None of the antibody positive participants in this 
study suffered with COVID-19 related symptoms during the fol-
low up time period, which might be taken to imply a level of 
protection against re-infection.
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LFT has an important role to play in virus and antibody de-
tection. Its benefits include being; safe, fast, cheap and high-
throughput, from a single finger prick blood sample, that avoids 
the need for laboratory analysis, and in terms of practicality for 
population screening outweigh claims of LFT having low sensi-
tivity and specificity, as confirmed here. LFT kits can be widely 
applied and require minimal training, however, in order to yield 
wide scale population data, it is important that standardization 
across the multitude of suppliers is introduced. A similar LFT 
based approach has been applied to screen local populations in 
areas of high incidence of COVID-19, where the LFT applied de-
tects SARS-CoV-2 virus, and has informed the widescale screen-
ing of the public [16,17]. 
Critically, COVID-19 vaccination is now being rolled out 
across the UK, with vaccination of front-line health care staff 
and the elderly already underway. Our results confirm LFT of-
fers the ability to monitor individual antibody production and 
thus the effectiveness of COVID-19 vaccination on a wide scale. 
This data could be collected over time to aid the understanding 
of COVID-19 antibody longevity and the effectiveness of anti-
body production in the prevention of COVID-19 infection.
Limitations 
It is acknowledged we have not at any time tested the par-
ticipants in this study for the presence of virus antigen and this 
could be considered a limitation of this study. We report howev-
er, on antibody prevalence in participants who either reported 
none or reported experiencing mild COVID-19 associated symp-
toms at any point in the previous 6 months. These participants 
were a-symptomatic at the time of testing for COVID-19 anti-
bodies and did not report a CRP level (indicative of recent acute 
infection) outside of the normal range (data not shown). 
We accept that this is a study of a relatively small and spe-
cific cohort and therefore may be classed as a limitation of this 
study. Importantly, this cohort equally represented both gen-
ders and covered a vast age range from 18 to 70 years old. Its 
specificity allows targeted results to be formed on this profes-
sional Welsh cohort. 
Conclusions
High sensitivity and specificity LFT for identification of anti-
bodies against COVID-19 performs extremely well when com-
pared against standard methods, and confirms this could be 
rolled out at low cost and with minimal user training. Apply-
ing LFT we confirm an antibody prevalence in our asymptom-
atic population of 3.65%. Within 6 months, 79.69% of antibody 
positive participants retained antibodies, with females being 4 
times more likely to lose antibodies against COVID-19. 
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